Chris Rhem

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.

Cooley advised Blue Owl Capital, a top asset manager that is redefining alternatives, on its strategic investment – consisting of a nondilutive, nonrecourse royalty-backed loan of up to $140 million – in XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.

Cooley advised Malibu Boats on its $350 million amended and restated revolver due July 2027. Malibu Boats is a leading designer and manufacturer of power boats in the US. Partner Mike Tollini and Ellie Guadiana led the Cooley team.

Cooley advised SoftBank Vision Fund 2 on its lead investment in Whoop’s $200 million Series F financing round, which brings the human performance company’s valuation to $3.6 billion. Lawyers Alex Kassai, Mary Wilbourn and Jack Culbertson led the Cooley team advising SoftBank Vision Fund 2.